Onsdag 6 Maj | 14:02:20 Europe / Stockholm

Bifogade filer

Kalender

Est. tid*
2026-08-11 17:10 Kvartalsrapport 2026-Q2
2026-03-06 - X-dag ordinarie utdelning DEMANT 0.00 DKK
2026-03-05 - Årsstämma
2026-02-03 - Bokslutskommuniké 2025
2025-08-12 - Kvartalsrapport 2025-Q2
2025-03-07 - X-dag ordinarie utdelning DEMANT 0.00 DKK
2025-03-06 - Årsstämma
2025-02-05 - Bokslutskommuniké 2024
2024-08-14 - Kvartalsrapport 2024-Q2
2024-03-07 - X-dag ordinarie utdelning DEMANT 0.00 DKK
2024-03-06 - Årsstämma
2024-02-06 - Bokslutskommuniké 2023
2023-08-15 - Kvartalsrapport 2023-Q2
2023-03-09 - X-dag ordinarie utdelning DEMANT 0.00 DKK
2023-03-08 - Årsstämma
2023-02-07 - Bokslutskommuniké 2022
2022-08-16 - Kvartalsrapport 2022-Q2
2022-03-11 - X-dag ordinarie utdelning DEMANT 0.00 DKK
2022-03-10 - Årsstämma
2022-02-08 - Bokslutskommuniké 2021
2021-08-12 - Kvartalsrapport 2021-Q2
2021-03-08 - X-dag ordinarie utdelning DEMANT 0.00 DKK
2021-03-05 - Årsstämma
2021-02-09 - Bokslutskommuniké 2020
2020-08-17 - Kvartalsrapport 2020-Q2
2020-03-11 - X-dag ordinarie utdelning DEMANT 0.00 DKK
2020-03-10 - Årsstämma
2020-02-04 - Bokslutskommuniké 2019
2019-08-14 - Kvartalsrapport 2019-Q2
2019-03-20 - X-dag ordinarie utdelning DEMANT 0.00 DKK
2019-03-19 - Årsstämma
2019-02-19 - Bokslutskommuniké 2018
2018-08-15 - Kvartalsrapport 2018-Q2
2018-03-23 - X-dag ordinarie utdelning DEMANT 0.00 DKK
2018-03-22 - Årsstämma
2018-02-22 - Bokslutskommuniké 2017
2017-08-14 - Kvartalsrapport 2017-Q2
2017-05-09 - Kvartalsrapport 2017-Q1
2017-03-28 - X-dag ordinarie utdelning DEMANT 0.00 DKK
2017-03-27 - Årsstämma
2017-02-23 - Bokslutskommuniké 2016
2016-11-10 - Kvartalsrapport 2016-Q3
2016-08-17 - Kvartalsrapport 2016-Q2
2016-05-25 - Split DEMANT 1:5
2016-05-10 - Kvartalsrapport 2016-Q1
2016-04-08 - X-dag ordinarie utdelning DEMANT 0.00 DKK
2016-04-07 - Årsstämma
2016-03-01 - Bokslutskommuniké 2015
2015-11-12 - Kvartalsrapport 2015-Q3
2015-08-14 - Kvartalsrapport 2015-Q2
2015-05-07 - Kvartalsrapport 2015-Q1
2015-04-10 - X-dag ordinarie utdelning DEMANT 0.00 DKK
2015-04-09 - Årsstämma
2015-02-26 - Bokslutskommuniké 2014
2014-11-13 - Kvartalsrapport 2014-Q3
2014-08-14 - Kvartalsrapport 2014-Q2
2014-05-08 - Kvartalsrapport 2014-Q1
2014-04-10 - X-dag ordinarie utdelning DEMANT 0.00 DKK
2014-04-09 - Årsstämma
2014-02-27 - Bokslutskommuniké 2013
2013-11-05 - Kvartalsrapport 2013-Q3
2013-08-14 - Kvartalsrapport 2013-Q2
2013-05-07 - Kvartalsrapport 2013-Q1
2013-04-10 - X-dag ordinarie utdelning DEMANT 0.00 DKK
2013-04-09 - Årsstämma
2013-02-26 - Bokslutskommuniké 2012
2012-11-07 - Kvartalsrapport 2012-Q3
2012-08-16 - Kvartalsrapport 2012-Q2
2012-05-10 - Kvartalsrapport 2012-Q1
2012-04-12 - X-dag ordinarie utdelning DEMANT 0.00 DKK
2012-04-11 - Årsstämma
2012-02-29 - Bokslutskommuniké 2011
2011-11-10 - Kvartalsrapport 2011-Q3
2011-08-19 - Kvartalsrapport 2011-Q2
2011-05-12 - Kvartalsrapport 2011-Q1
2011-04-14 - X-dag ordinarie utdelning DEMANT 0.00 DKK
2011-04-13 - Årsstämma
2010-11-16 - Kvartalsrapport 2010-Q3
2010-04-08 - X-dag ordinarie utdelning DEMANT 0.00 DKK

Beskrivning

LandDanmark
ListaLarge Cap Copenhagen
SektorHälsovård
IndustriMedicinteknik
Demant är verksamt inom medicinteknik. Bolaget är specialiserat inom utveckling av hörapparater och hörslingor. Bolaget innehar verksamhet på global nivå där produkterna säljs under varierande varumärken. Produkterna nås via bolagets distributörer och försäljningskanaler. Utöver huvudverksamheten bedriver bolaget forskning inom diagnostik för mätning av hörselkvalitén. Bolaget grundades ursprungligen år 1904 och har sitt huvudkontor i Smörum.

Intresserad av bolagets nyckeltal?

Analysera bolaget i Börsdata!

Vem äger bolaget?

All ägardata du vill ha finns i Holdings!

2026-05-06 12:30:10

6.5.2026 12:30:06 CEST | Demant A/S | Investor News

Investor news

6 May 2026

Expansion of Demant’s Executive Leadership Team

New President of Hearing Aids and member of Demant’s Executive Leadership Team
Søren Nielsen to fully focus on his position as President & CEO of Demant 

 

Effective 1 June 2026, Bassel Rifai will join Demant as President of the Hearing Aids business area and become a member of the Executive Leadership Team and thus take part in driving Demant’s strategy forward.

 

As part of this change, Søren Nielsen will step out of his role as President of Hearing Aids to focus fully on his position as President & CEO of the Demant Group. Since assuming the role of CEO of the Demant Group in 2017, Søren Nielsen has concurrently held the position as President of Hearing Aids. During this period, Demant almost doubled in size. This development supports a strengthened focus on the continued execution of the Group’s strategy and reflects the significant potential for further value creation and cross-business collaboration, enabled by Søren Nielsen’s industry knowledge, as he will now focus fully on the Group’s overall strategy and performance.

 

“I am pleased to welcome Bassel Rifai as the new President of Hearing Aids and member of Demant’s Executive Leadership Team. With a strategic mindset, Bassel brings a strong combination of a background in engineering and deep commercial leadership experience in medical technologies. With his in-depth understanding of healthcare markets, I am confident that Bassel, supported by the Hearing Aids leadership team and thousands of dedicated and passionate colleagues around the world, is the right profile to ensure that our Hearing Aids business continues to deliver industry-leading innovation and growth,” says Søren Nielsen, President & CEO of Demant.

 

Commenting on his new role, Bassel Rifai says: “I’m very excited to join Demant at an important point in its growth journey. The company has a proud 120-year legacy and impressive track record of innovation and growth, with even more potential ahead to address hearing loss. I am inspired by the company’s purpose, to create life-changing differences through hearing health. And I look forward to leading the Hearing Aids organisation to advance our market position and deliver meaningful outcomes for users and customers.”

 

Bassel Rifai has spent the majority of his career in international medical technology companies. Most recently, he served as EVP & President of EMEA & APAC at Ambu. Prior to that, he held senior leadership positions at Johnson & Johnson in global, US, and European roles, across marketing, general management and sales. Before that, he worked in management consulting at McKinsey & Company. Bassel holds a PhD in Biomedical Engineering from the University of Oxford and a Bachelor of Science in Electrical Engineering from UCLA.

 

Curriculum vitae – Bassel Rifai

2021 – now: Ambu

  • EVP & President EMEA & APAC
  • SVP Chief Marketing Officer 

2014 – 2021: Johnson & Johnson

  • Vice President, Global & US Marketing – Spine
  • General Manager – US Osteo-biologics
  • Sales Director – UK Orthopedics 
  • Director – Orthopedics EMEA

2011 – 2014: McKinsey & Company

  • Engagement Manager – Healthcare

 

Further information:

Søren Nielsen, President & CEO

Phone +45 3917 7300

www.demant.com

Other contacts:

René Schneider, CFO

Peter Pudselykke, Head of Investor Relations

Gustav Høegh, Investor Relations Officer

Maribel Alonso Francisco, Communication Manager

 

 

Contacts

About Demant A/S

Demant is a world-leading hearing healthcare group that offers innovative technologies, solutions and expertise to help people hear better. In every aspect, from hearing care and hearing aids to diagnostic equipment and services, Demant is active and engaged. Headquartered in Denmark, the Group employs more than 26,000 people globally and is present with solutions in 130 countries creating life-changing differences through hearing health. William Demant Foundation holds the majority of shares in Demant A/S, which is listed on Nasdaq Copenhagen and among the 25 most traded stocks.

Attachments